Agilent Technologies
A stock analysis · Health Care · Life Sciences Tools & Services
As of · fund-implied per-share value
Fund holding value ÷ shares held. Not a live quote; not adjusted for later stock splits.
View SEC fund filing ↗Price × SEC outstanding shares. Shares measured 2026-05-27. Approximate; share and price dates can differ.
View share-count filing ↗DCF value
Equity cash-flow scenario · SEC outstanding shares at 2026-05-27 · -53.4% versus input cap
How this is calculated ↗Reverse DCF
Annual basis · read assumptions below
How this is calculated ↗Relative valuation
6 industry peers · median 33.2×
How this is calculated ↗Historical multiples
7 annual observations · snapshot P/E 28.8× · -12.4% versus history
How this is calculated ↗Free cash flow yield
Annual basis · read assumptions below
How this is calculated ↗ROIC / quality
Normalized tax · financing-capital proxy · parent-equity fallback (scope limitation)
How this is calculated ↗Value composite
Annual basis · read assumptions below
How this is calculated ↗12–1 price momentum
Split and corporate-action verification is incomplete for these fund observations. Verified adjusted endpoints are required for 12–1 momentum.
How this is calculated ↗Asset growth
Annual basis · read assumptions below
How this is calculated ↗Net payout yield
Annual basis · read assumptions below
How this is calculated ↗Accrual quality
Parent-earnings fallback versus consolidated cash flow · scope limitation
How this is calculated ↗Fundamental momentum
Annual basis · read assumptions below
How this is calculated ↗Follow the cash
ANNUAL · USDOperating cash flow and reinvestment over time
Annual USD. Negative bars use a compressed lower scale. Hover or inspect the financial history table for exact values.
Make the assumptions yours
How sensitive is the valuation?
| Return / Growth | 3.0% | 5.0% | 7.0% |
|---|---|---|---|
| 8.0% | $77.71 | $84.78 | $92.40 |
| 10.0% | $56.94 | $61.95 | $67.33 |
| 12.0% | $44.92 | $48.75 | $52.84 |
Annual financial history
Open SEC filings ↗| Fiscal year-end | Revenue | Net income | Operating cash flow | Capital expenditure | Assets |
|---|---|---|---|---|---|
| 2025-10-31 | 6.9B | 1.3B | 1.6B | 407M | 12.7B |
| 2024-10-31 | 6.5B | 1.3B | 1.8B | 378M | 11.8B |
| 2023-10-31 | 6.8B | 1.2B | 1.8B | 298M | 10.8B |
| 2022-10-31 | 6.8B | 1.3B | 1.3B | 291M | 10.5B |
| 2021-10-31 | 6.3B | 1.2B | 1.5B | 188M | 10.7B |
| 2020-10-31 | 5.3B | 719M | 921M | 119M | 9.6B |
| 2019-10-31 | 5.2B | 1.1B | 1B | 155M | 9.5B |
| 2018-10-31 | 4.9B | 316M | 1.1B | 177M | 8.5B |
USD, abbreviated. Restated annual history; not a point-in-time backtest. Missing values appear as dashes.
Trace the inputs
MODEL ANNUAL PERIOD| Input | Value | SEC tag / source | Filed |
|---|---|---|---|
| revenue | 6.9B | RevenueFromContractWithCustomerExcludingAssessedTax | 2025-12-22 |
| netIncome | 1.3B | NetIncomeLoss Parent-attributable fallback: a verified consolidated total is unavailable in the supported tags. Noncontrolling interests have not been assumed to be zero; this may differ in scope from consolidated cash flow or operating income. | 2025-12-22 |
| Parent/common earnings proxy | 1.3B | NetIncomeLoss | 2025-12-22 |
| cfo | 1.6B | NetCashProvidedByUsedInOperatingActivities | 2025-12-22 |
| capex | 407M | PaymentsToAcquirePropertyPlantAndEquipment | 2025-12-22 |
| operatingIncome | 1.5B | OperatingIncomeLoss | 2025-12-22 |
| assets | 12.7B | Assets | 2025-12-22 |
| equity | 6.7B | StockholdersEquity Parent-attributable fallback: a verified consolidated total is unavailable in the supported tags. Noncontrolling interests have not been assumed to be zero; this may differ in scope from consolidated cash flow or operating income. | 2025-12-22 |
| Parent book equity proxy | 6.7B | StockholdersEquity | 2025-12-22 |
| debt | 3.1B | LongTermDebt | 2025-12-22 |
| shortDebt | 304M | ShortTermBorrowings | 2025-12-22 |
| cash | 1.8B | CashAndCashEquivalentsAtCarryingValue | 2025-12-22 |
| shares | 285M | WeightedAverageNumberOfDilutedSharesOutstanding | 2025-12-22 |
| dividends | 282M | PaymentsOfDividendsCommonStock | 2025-12-22 |
| buybacks | 425M | PaymentsForRepurchaseOfCommonStock | 2025-12-22 |
| issuance | 72M | Reviewed manual correction Bounded FY2025-10-31 consolidated financing-statement extraction. Proceeds from the issuance of common stock under employee stock plans: 72000000 USD [us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions]. All 10 financing lines reconcile exactly to reported financing cash flow -715000000 USD. Cash inflows from common shares, employee plans and option exercises are summed once as displayed on the statement; noncash compensation, withholding payments, preferred and noncontrolling interests are excluded. This review applies only to this issuer and fiscal period. Source limitation: issuance follows the separately reported common cash-inflow lines; it is not an independent verification of every gross equity transaction. | 2025-12-22 |